Velarion · Company Intelligence
Compensation Brief
Fiscal year 2023 · Filings through 2026-04-29

Paragon 28 (FNA)

CEO Albert DaCosta was paid $3,232,420 in fiscal year 2023, ↓ down 38.0% from fiscal year 2022, the 7th percentile of its disclosed peer group (SEC filing 0001193125-24-088613 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$3,232,420 ↓
Albert DaCosta total, FY2023
7th
CEO pay percentile vs peers
—
CEO-to-median pay ratio
—
Say-on-pay support, latest vote

Track this company's pay every filing: join the Pro seat waitlist

Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year

A confirmation now and one email when Pro opens, and nothing else. Privacy

01

Summary Compensation Table — fiscal year 2023

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Albert DaCosta$700,769$0$1,832,495$0$667,400$0$31,757$3,232,420
Chairman, President and Chief Executive Officer
Matthew Jarboe538,5310635,0030329,940031,4451,534,918
Chief Commercial Officer
Stephen Deitsch478,3850698,9950296,335031,7571,505,471
Chief Financial Officer
Robert McCormack148,9230924,994078,58408,7641,161,265
General Counsel and Corporate Secretary
Jason Edie221,16282,156463,001000388,9491,155,268
Former Chief Technology Officer
Andrew Hill57,6920999,9920003,7591,061,444
Executive Vice President of Research and Development

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2023 totalFY2022 totalFY2021 totalΔ FY2022→2023
Albert DaCosta$3,232,420$5,214,743$4,650,087↓ −1,982,323
Matthew Jarboe1,534,9182,255,3902,097,440↓ −720,472
Stephen Deitsch1,505,4712,224,3211,895,603↓ −718,850
Robert McCormack1,161,265———
Jason Edie1,155,2682,457,580—↓ −1,302,312
Andrew Hill1,061,444———

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

You have just read Paragon 28's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper FNA reports.

We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.

How we handle your data → Privacy

Companies that benchmark against FNA
7 companies name FNA as a compensation peer

The list of companies that name FNA as a peer is temporarily unavailable — recheck shortly.

01c

Board of directors

One page per director: the seat, the committees and the fee table, read for one person at a time.

DirectorRoleFY2023 total
Alf GrunwaldIndependent Director$210,000
B. Kristine JohnsonIndependent Director$212,500
Kristina WrightDirector$220,000
Meghan ScanlonIndependent Director$210,611
Quentin BlackfordIndependent Director$220,000
Stephen OesterleIndependent Director$210,000
Thomas SchnettlerLead Independent Director$245,000
02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2023 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
MVM Partners, LLCGreater-than-10% holder2025-01-23D20,136$12$234,101Common, indirectForm 4 ↗
MVM Partners, LLCGreater-than-10% holder2025-01-24D25,02612290,176Common, indirectForm 4 ↗
MVM Partners, LLCGreater-than-10% holder2025-01-27D27,14212315,425Common, indirectForm 4 ↗
MVM Partners, LLCGreater-than-10% holder2025-01-28D84,323121,006,648Common, indirectForm 4 ↗
Matthew JarboeChief Commercial Officer2025-02-28D4,1361353,933CommonForm 4 ↗
Albert DaCostaDirector2025-02-28D11,34113147,887CommonForm 4 ↗
MVM Partners, LLCGreater-than-10% holder2025-03-04D619,747138,053,116Common, indirectForm 4 ↗
MVM Partners, LLCGreater-than-10% holder2025-03-05D590,224137,684,362Common, indirectForm 4 ↗
MVM Partners, LLCGreater-than-10% holder2025-03-06D164,664132,142,592Common, indirectForm 4 ↗
Robert McCormackSee Remarks2025-03-10D8,16513106,227CommonForm 4 ↗
Albert DaCostaDirector2025-03-10D18,25813237,537CommonForm 4 ↗
Matthew JarboeChief Commercial Officer2025-03-10D10,73213139,623CommonForm 4 ↗
MVM Partners, LLCGreater-than-10% holder2025-03-13D1,044,2951313,618,129Common, indirectForm 4 ↗
Albert DaCostaDirector2025-03-14A2,061,70200CommonForm 4 ↗
Albert DaCostaDirector2025-03-14D2,061,70200CommonForm 4 ↗
Andrew HillEVP of Research & Development2025-03-20A49,88400CommonForm 4 ↗
Robert McCormackSee Remarks2025-03-20A90,86700CommonForm 4 ↗
Albert DaCostaDirector2025-03-20A337,68200CommonForm 4 ↗
Matthew JarboeChief Commercial Officer2025-03-20A117,34400CommonForm 4 ↗
Chadi ChahineSee Remarks2025-03-20A145,81700CommonForm 4 ↗
Thomas SchnettlerDirector2025-04-21D45,035——CommonForm 4 ↗
David M. DemskiDirector2025-04-21D74,307——CommonForm 4 ↗
Albert DaCostaDirector2025-04-21D233,694——Derivative, Class A CommonForm 4 ↗
Albert DaCostaDirector2025-04-21D2,061,702——CommonForm 4 ↗
Albert DaCostaDirector2025-04-21D3,277,408——CommonForm 4 ↗
Albert DaCostaDirector2025-04-21D1,314,614——CommonForm 4 ↗
Chadi ChahineSee Remarks2025-04-21D174,769——Derivative, Class A CommonForm 4 ↗
Quentin BlackfordDirector2025-04-21D50,554——CommonForm 4 ↗
Andrew HillEVP of Research & Development2025-04-21D126,397——CommonForm 4 ↗
Matthew JarboeChief Commercial Officer2025-04-21D155,210——Derivative, Class A CommonForm 4 ↗
Matthew JarboeChief Commercial Officer2025-04-21D175,000——Derivative, Class A CommonForm 4 ↗
Matthew JarboeChief Commercial Officer2025-04-21D50,000——Derivative, Class A CommonForm 4 ↗
Matthew JarboeChief Commercial Officer2025-04-21D50,000——Derivative, Class A CommonForm 4 ↗
Matthew JarboeChief Commercial Officer2025-04-21D575,320——CommonForm 4 ↗
B. Kristine JohnsonDirector2025-04-21D47,347——CommonForm 4 ↗
Stephen OesterleDirector2025-04-21D250,000——Derivative, Class A CommonForm 4 ↗
Stephen OesterleDirector2025-04-21D40,216——CommonForm 4 ↗
Meghan ScanlonDirector2025-04-21D42,113——CommonForm 4 ↗
Robert McCormackSee Remarks2025-04-21D20,014——Derivative, Class A CommonForm 4 ↗
Robert McCormackSee Remarks2025-04-21D203,134——CommonForm 4 ↗
Albert DaCostaDirector2025-04-21D450,778——Derivative, Class A CommonForm 4 ↗
Albert DaCostaDirector2025-04-21D75,000——Derivative, Class A CommonForm 4 ↗
Albert DaCostaDirector2025-04-21D37,500——Derivative, Class A CommonForm 4 ↗
Albert DaCostaDirector2025-04-21D50,000——Derivative, Class A CommonForm 4 ↗
Chadi ChahineSee Remarks2025-04-21D520,657——CommonForm 4 ↗
Matthew JarboeChief Commercial Officer2025-04-21D27,588——Derivative, Class A CommonForm 4 ↗
Albert DaCostaDirector2025-04-21D75,000——Derivative, Class A CommonForm 4 ↗
Andrew HillEVP of Research & Development2025-04-21D10,818——Derivative, Class A CommonForm 4 ↗
Kristina WrightDirector2025-04-21D32,118——CommonForm 4 ↗
Alf GrunwaldDirector2025-04-21D51,935——CommonForm 4 ↗
Albert DaCostaDirector2025-04-21D125,000——Derivative, Class A CommonForm 4 ↗
Albert DaCostaDirector2025-04-21D125,000——Derivative, Class A CommonForm 4 ↗
Albert DaCostaDirector2025-04-21D100,000——CommonForm 4 ↗
Albert DaCostaDirector2025-04-21D5,000,000——CommonForm 4 ↗
Matthew JarboeChief Commercial Officer2025-04-21D37,500——Derivative, Class A CommonForm 4 ↗
Matthew JarboeChief Commercial Officer2025-04-21D75,000——Derivative, Class A CommonForm 4 ↗
Matthew JarboeChief Commercial Officer2025-04-21D25,000——Derivative, Class A CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

03

Grants of plan-based awards — fiscal year 2023

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Stephen DeitschRSU2023-02-28——39,050—$698,995
Andrew HillRSU2023-10-23——85,910—999,992
Matthew JarboeRSU2023-02-28——35,475—635,003
Jason EdiePSU2023-02-28—25,866——463,001
Albert DaCostaRSU2023-02-28——102,374—1,832,495
Robert McCormackPSU2023-08-14—54,961——924,994
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Stephen Deitsch$698,995$0$00.0%
Andrew Hill999,992000.0%
Matthew Jarboe635,003000.0%
Jason Edie0463,0010100.0%
Albert DaCosta1,832,495000.0%
Robert McCormack0924,9940100.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2023

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Matthew JarboeRSU35,475—$440,954
Robert McCormackRSU85,910—1,067,861
Stephen DeitschRSU59,004—733,420
Albert DaCostaRSU102,374—1,272,509
Albert DaCostaRSU154,684—1,922,722
Robert McCormackRSU54,961—683,165
Stephen DeitschOption125,0006—
Robert McCormackRSU6,467—80,385
Matthew JarboeRSU53,601—666,260
Stephen DeitschRSU39,050—485,392
Albert DaCostaOption206,60916—
Stephen DeitschOption71,13116—
Robert McCormackOption51,23017.72—
Matthew JarboeOption71,13116—
05

Incentive-plan design — the Compensation Discussion & Analysis

Historically, our executive compensation program has been designed to motivate, reward, attract and retain high caliber management deemed critical to our success. The program seeks to align executive compensation with our short-term and long-term objectives, financial performance and stockholder priorities.

CEO STI target (% of salary)100%
CEO LTI target (% of salary)—
Independent consultantCompensia, Inc.
Clawback policyTrue
Anti-hedgingTrue
Anti-pledgingTrue
08

Director compensation — fiscal year 2023

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Thomas SchnettlerIndependent · Lead Independent Director · Audit$95,000$150,000$0—$0$245,000
Kristina WrightEmployee director · Audit (Chair)70,000150,0000—0220,000
Quentin BlackfordIndependent · Audit · Compensation (Chair)70,000150,0000—0220,000
B. Kristine JohnsonIndependent · Compensation · Nominating and Corporate Governance (Chair)62,500150,0000—0212,500
Meghan ScanlonIndependent · Compensation · Nominating and Corporate Governance · Quality, Technology and Regulatory60,611150,0000—0210,611
Alf GrunwaldIndependent · Audit · Quality, Technology and Regulatory60,000150,0000—0210,000
Stephen OesterleIndependent · Nominating and Corporate Governance · Quality, Technology and Regulatory (Chair)60,000150,0000—0210,000
Albert DaCostaEmployee director · Board Chair000—00
09

Board fee structure and ownership guideline

Annual cash retainer$45,000
Annual equity retainer$150,000
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)—
Stock ownership guideline4x annual retainer
09b

Total cost of the board

ComponentFY2023
Cash retainers and fees$478,111
Equity awards (grant-date value)$1,050,000
All other compensation$0
Total cost of the board$1,528,111

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2023

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

10a

Peer reciprocity

Of the companies Paragon 28 names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Paragon 28.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Silk Road Medical2023Chas McKhann$105,871$13,123,059$0$93,275$13,423,834
2Glaukos2025Thomas Burns850,0007,649,9473,527,497012,034,087
3Nevro2023Kevin Thornal515,62510,080,1730402,75011,453,548
4Vericel2025Dominick Colangelo860,0003,964,6305,456,287860,00011,156,368
5iRhythm Technologies2025Quentin Blackford700,0038,919,45701,350,00011,003,163
6Alphatec Holdings2025Patrick Miles762,0008,859,6500600,00010,260,507
7AtriCure2025Michael Carrel828,4397,203,47801,171,7039,217,620
8AxoGen2025Michael Dale775,8657,342,8950906,1339,047,454
9SI-BONE2025Laura Francis685,0006,038,7100729,5257,453,235
10Orthofix Medical2025Massimo Calafiore848,3224,499,9881,500,009445,5797,310,039
11Tandem Diabetes Care2025John Sheridan790,5835,367,7960674,0906,858,503
12Treace Medical Concepts2025John Treace755,3534,635,000005,405,190
13Inari Medical2023Andrew Hykes700,0002,606,744937,488826,0005,083,365
14LeMaitre Vascular2025George LeMaitre806,3471,050,0001,050,000680,0153,780,990
15Paragon 282023Albert DaCosta700,7691,832,4950667,4003,232,420
16Cryoport2025Jerrell Shelton967,845192,300306,869908,5102,375,524
—Axonics——————not in coverage universe

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
Paragon 2894%RSU 100not disclosedCompensia, Inc.
Alphatec Holdings157%PSU 50 · RSU 50NoCompensia
AtriCure141%PSU 70 · RSU 30NoKorn Ferry
AxoGen116.79%PSU 50 · RSU 50NoAon
Axonicsnot disclosednot disclosednot disclosednot disclosed
Cryoport92.2%not disclosednot disclosedFrederic W. Cook & Co., Inc.
Glaukos177.5%RSU 50 · PRSU 50NoFrederic W. Cook & Co., Inc.
Inari Medical118%RSU 75 · Option 25not disclosedFW Cook
iRhythm Technologies173%RSU 50 · PSU 50Yes — Relative TSRAon and Mercer
LeMaitre Vascularnot disclosedOption 50 · RSU 25 · PSU 25Nonot disclosed
Nevro53.7%not disclosedNoAon
Orthofix Medical47.7%PSU 50 · Option 25 · RSU 25NoMeridian
SI-BONE106.5%RSU 50 · PSU 50Yes — Relative TSRCompensia, Inc.
Silk Road Medicalnot disclosedPSU 50 · RSU 50Yes — Total Stockholder Return (TSR) relative to peer groupCompensia, Inc.
Tandem Diabetes Care87%PSU 50 · RSU 50Yes — TSR performance compared to the Russell 3000 index in the three-year period between 2025 and 2027WTW
Treace Medical Conceptsnot disclosedRSU 50 · PSU 50NoCompensia, Inc.
Vericel100%Options 58 · RSU 42not disclosedFW Cook

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

10d

Frequently asked questions

Who was the highest-paid executive at Paragon 28 in fiscal 2023?
As disclosed, Albert DaCosta (Chairman, President and Chief Executive Officer) was the highest-paid executive at Paragon 28 in fiscal 2023, with total compensation of $3,232,420.
How does Paragon 28's chief executive pay compare to its disclosed peer group?
As disclosed, Albert DaCosta's total compensation ranked at the 7th percentile of Paragon 28's disclosed peer group.
How much does Paragon 28 spend in total on board compensation for fiscal 2023?
As disclosed, Paragon 28 reported total board compensation of $1,528,111 for fiscal 2023.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Albert DaCostaDEF 14A2024-04-050001193125-24-088613Section “2023 Summary Compensation Table” · page 51. As printed: 3,232,420. Filing ↗machine: t193 · r2 · c31 · span 598805–598814
2Section 01, Matthew JarboeDEF 14A2024-04-050001193125-24-088613Section “2023 Summary Compensation Table” · page 51. As printed: 1,534,918. Filing ↗machine: t193 · r8 · c31 · span 612738–612747
3Section 01, Stephen DeitschDEF 14A2024-04-050001193125-24-088613Section “2023 Summary Compensation Table” · page 51. As printed: 1,505,471. Filing ↗machine: t193 · r5 · c31 · span 605886–605895
4Section 01, Robert McCormackDEF 14A2024-04-050001193125-24-088613Section “2023 Summary Compensation Table” · page 51. As printed: 1,161,265. Filing ↗machine: t193 · r11 · c31 · span 619670–619679
5Section 01, Jason EdieDEF 14A2024-04-050001193125-24-088613Section “2023 Summary Compensation Table” · page 51. As printed: 1,155,268. Filing ↗machine: t193 · r17 · c31 · span 630884–630893
6Section 01, Andrew HillDEF 14A2024-04-050001193125-24-088613Section “2023 Summary Compensation Table” · page 51. As printed: 1,061,444. Filing ↗machine: t193 · r14 · c31 · span 625364–625373
7Section 03, Stephen Deitsch RSUDEF 14A2024-04-050001193125-24-088613Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t193 · r5 · c15 · span 604871–604878
8Section 03, Andrew Hill RSUDEF 14A2024-04-050001193125-24-088613Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t193 · r14 · c15 · span 624338–624345
9Section 03, Matthew Jarboe RSUDEF 14A2024-04-050001193125-24-088613Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t193 · r8 · c15 · span 611723–611730
10Section 03, Jason Edie PSUDEF 14A2024-04-050001193125-24-088613Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t193 · r17 · c15 · span 629856–629863
11Section 03, Albert DaCosta RSUDEF 14A2024-04-050001193125-24-088613Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t193 · r2 · c15 · span 597788–597797
12Section 03, Robert McCormack PSUDEF 14A2024-04-050001193125-24-088613Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t193 · r11 · c15 · span 618657–618664
13Section 08, Thomas SchnettlerDEF 14A2024-04-050001193125-24-088613Section “Director Compensation”. As printed: 245,000. Filing ↗machine: t109 · r7 · c11 · span 367985–367992
14Section 08, Kristina WrightDEF 14A2024-04-050001193125-24-088613Section “Director Compensation”. As printed: 220,000. Filing ↗machine: t109 · r8 · c11 · span 369129–369136
15Section 08, Quentin BlackfordDEF 14A2024-04-050001193125-24-088613Section “Director Compensation”. As printed: 220,000. Filing ↗machine: t109 · r2 · c11 · span 362610–362617
16Section 08, B. Kristine JohnsonDEF 14A2024-04-050001193125-24-088613Section “Director Compensation”. As printed: 212,500. Filing ↗machine: t109 · r4 · c11 · span 364763–364770
17Section 08, Meghan ScanlonDEF 14A2024-04-050001193125-24-088613Section “Director Compensation”. As printed: 210,611. Filing ↗machine: t109 · r6 · c11 · span 366920–366927
18Section 08, Alf GrunwaldDEF 14A2024-04-050001193125-24-088613Section “Director Compensation”. As printed: 210,000. Filing ↗
19Section 08, Stephen OesterleDEF 14A2024-04-050001193125-24-088613Section “Director Compensation”. As printed: 210,000. Filing ↗machine: t109 · r5 · c11 · span 365833–365840
20Section 08, Albert DaCostaDEF 14A2024-04-050001193125-24-088613Section “Director Compensation”. As printed: 0. Filing ↗
21Section 02, MVM Partners, LLC 2025-01-23Form 42025-01-270001104659-25-006316Insider equity transaction reported since the proxy statement. Filing ↗
22Section 02, MVM Partners, LLC 2025-01-24Form 42025-01-270001104659-25-006316Insider equity transaction reported since the proxy statement. Filing ↗
23Section 02, MVM Partners, LLC 2025-01-27Form 42025-01-290001104659-25-007285Insider equity transaction reported since the proxy statement. Filing ↗
24Section 02, MVM Partners, LLC 2025-01-28Form 42025-01-290001104659-25-007285Insider equity transaction reported since the proxy statement. Filing ↗
25Section 02, Matthew Jarboe 2025-02-28Form 42025-03-040001610717-25-000057Insider equity transaction reported since the proxy statement. Filing ↗
26Section 02, Albert DaCosta 2025-02-28Form 42025-03-040001610717-25-000058Insider equity transaction reported since the proxy statement. Filing ↗
27Section 02, MVM Partners, LLC 2025-03-04Form 42025-03-060001104659-25-021439Insider equity transaction reported since the proxy statement. Filing ↗
28Section 02, MVM Partners, LLC 2025-03-05Form 42025-03-060001104659-25-021439Insider equity transaction reported since the proxy statement. Filing ↗
29Section 02, MVM Partners, LLC 2025-03-06Form 42025-03-060001104659-25-021439Insider equity transaction reported since the proxy statement. Filing ↗
30Section 02, Robert McCormack 2025-03-10Form 42025-03-120001610717-25-000062Insider equity transaction reported since the proxy statement. Filing ↗
31Section 02, Albert DaCosta 2025-03-10Form 42025-03-120001610717-25-000060Insider equity transaction reported since the proxy statement. Filing ↗
32Section 02, Matthew Jarboe 2025-03-10Form 42025-03-120001610717-25-000061Insider equity transaction reported since the proxy statement. Filing ↗
33Section 02, MVM Partners, LLC 2025-03-13Form 42025-03-130001104659-25-023576Insider equity transaction reported since the proxy statement. Filing ↗
34Section 02, Albert DaCosta 2025-03-14Form 42025-03-180001610717-25-000072Insider equity transaction reported since the proxy statement. Filing ↗
35Section 02, Albert DaCosta 2025-03-14Form 42025-03-180001610717-25-000072Insider equity transaction reported since the proxy statement. Filing ↗
36Section 02, Andrew Hill 2025-03-20Form 42025-03-240001610717-25-000092Insider equity transaction reported since the proxy statement. Filing ↗
37Section 02, Robert McCormack 2025-03-20Form 42025-03-240001610717-25-000090Insider equity transaction reported since the proxy statement. Filing ↗
38Section 02, Albert DaCosta 2025-03-20Form 42025-03-240001610717-25-000089Insider equity transaction reported since the proxy statement. Filing ↗
39Section 02, Matthew Jarboe 2025-03-20Form 42025-03-240001610717-25-000091Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, Chadi Chahine 2025-03-20Form 42025-03-240001610717-25-000093Insider equity transaction reported since the proxy statement. Filing ↗
41Section 02, Thomas Schnettler 2025-04-21Form 42025-04-210000950170-25-056368Insider equity transaction reported since the proxy statement. Filing ↗
42Section 02, David M. Demski 2025-04-21Form 42025-04-210000950170-25-056357Insider equity transaction reported since the proxy statement. Filing ↗
43Section 02, Albert DaCosta 2025-04-21Form 42025-04-210000950170-25-056358Insider equity transaction reported since the proxy statement. Filing ↗
44Section 02, Albert DaCosta 2025-04-21Form 42025-04-210000950170-25-056358Insider equity transaction reported since the proxy statement. Filing ↗
45Section 02, Albert DaCosta 2025-04-21Form 42025-04-210000950170-25-056358Insider equity transaction reported since the proxy statement. Filing ↗
46Section 02, Albert DaCosta 2025-04-21Form 42025-04-210000950170-25-056358Insider equity transaction reported since the proxy statement. Filing ↗
47Section 02, Chadi Chahine 2025-04-21Form 42025-04-210000950170-25-056363Insider equity transaction reported since the proxy statement. Filing ↗
48Section 02, Quentin Blackford 2025-04-21Form 42025-04-210000950170-25-056364Insider equity transaction reported since the proxy statement. Filing ↗
49Section 02, Andrew Hill 2025-04-21Form 42025-04-210000950170-25-056361Insider equity transaction reported since the proxy statement. Filing ↗
50Section 02, Matthew Jarboe 2025-04-21Form 42025-04-210000950170-25-056365Insider equity transaction reported since the proxy statement. Filing ↗
51Section 02, Matthew Jarboe 2025-04-21Form 42025-04-210000950170-25-056365Insider equity transaction reported since the proxy statement. Filing ↗
52Section 02, Matthew Jarboe 2025-04-21Form 42025-04-210000950170-25-056365Insider equity transaction reported since the proxy statement. Filing ↗
53Section 02, Matthew Jarboe 2025-04-21Form 42025-04-210000950170-25-056365Insider equity transaction reported since the proxy statement. Filing ↗
54Section 02, Matthew Jarboe 2025-04-21Form 42025-04-210000950170-25-056365Insider equity transaction reported since the proxy statement. Filing ↗
55Section 02, B. Kristine Johnson 2025-04-21Form 42025-04-210000950170-25-056366Insider equity transaction reported since the proxy statement. Filing ↗
56Section 02, Stephen Oesterle 2025-04-21Form 42025-04-210000950170-25-056367Insider equity transaction reported since the proxy statement. Filing ↗
57Section 02, Stephen Oesterle 2025-04-21Form 42025-04-210000950170-25-056367Insider equity transaction reported since the proxy statement. Filing ↗
58Section 02, Meghan Scanlon 2025-04-21Form 42025-04-210000950170-25-056369Insider equity transaction reported since the proxy statement. Filing ↗
59Section 02, Robert McCormack 2025-04-21Form 42025-04-210000950170-25-056370Insider equity transaction reported since the proxy statement. Filing ↗
60Section 02, Robert McCormack 2025-04-21Form 42025-04-210000950170-25-056370Insider equity transaction reported since the proxy statement. Filing ↗
61Section 02, Albert DaCosta 2025-04-21Form 42025-04-210000950170-25-056358Insider equity transaction reported since the proxy statement. Filing ↗
62Section 02, Albert DaCosta 2025-04-21Form 42025-04-210000950170-25-056358Insider equity transaction reported since the proxy statement. Filing ↗
63Section 02, Albert DaCosta 2025-04-21Form 42025-04-210000950170-25-056358Insider equity transaction reported since the proxy statement. Filing ↗
64Section 02, Albert DaCosta 2025-04-21Form 42025-04-210000950170-25-056358Insider equity transaction reported since the proxy statement. Filing ↗
65Section 02, Chadi Chahine 2025-04-21Form 42025-04-210000950170-25-056363Insider equity transaction reported since the proxy statement. Filing ↗
66Section 02, Matthew Jarboe 2025-04-21Form 42025-04-210000950170-25-056365Insider equity transaction reported since the proxy statement. Filing ↗
67Section 02, Albert DaCosta 2025-04-21Form 42025-04-210000950170-25-056358Insider equity transaction reported since the proxy statement. Filing ↗
68Section 02, Andrew Hill 2025-04-21Form 42025-04-210000950170-25-056361Insider equity transaction reported since the proxy statement. Filing ↗
69Section 02, Kristina Wright 2025-04-21Form 42025-04-210000950170-25-056360Insider equity transaction reported since the proxy statement. Filing ↗
70Section 02, Alf Grunwald 2025-04-21Form 42025-04-210000950170-25-056359Insider equity transaction reported since the proxy statement. Filing ↗
71Section 02, Albert DaCosta 2025-04-21Form 42025-04-210000950170-25-056358Insider equity transaction reported since the proxy statement. Filing ↗
72Section 02, Albert DaCosta 2025-04-21Form 42025-04-210000950170-25-056358Insider equity transaction reported since the proxy statement. Filing ↗
73Section 02, Albert DaCosta 2025-04-21Form 42025-04-210000950170-25-056358Insider equity transaction reported since the proxy statement. Filing ↗
74Section 02, Albert DaCosta 2025-04-21Form 42025-04-210000950170-25-056358Insider equity transaction reported since the proxy statement. Filing ↗
75Section 02, Matthew Jarboe 2025-04-21Form 42025-04-210000950170-25-056365Insider equity transaction reported since the proxy statement. Filing ↗
76Section 02, Matthew Jarboe 2025-04-21Form 42025-04-210000950170-25-056365Insider equity transaction reported since the proxy statement. Filing ↗
77Section 02, Matthew Jarboe 2025-04-21Form 42025-04-210000950170-25-056365Insider equity transaction reported since the proxy statement. Filing ↗
78Section 01 trend, Δ column (computed)Computed——Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
79Section 03b vehicle mix (computed)Computed——RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
80Section 09b board cost (computed)Computed——Cash 478,111 + equity 1,050,000 + all other 0 = 1,528,111, summed across the director compensation table rows.machine: formula: Σ = 1,528,111
81Silk Road Medical, Section 10b CEO totalDEF 14A2024-04-260001397702-24-000024CEO total compensation as printed in Silk Road Medical's own proxy. As printed: 13,423,834. Filing ↗machine: r2 · c8 · span 1756696–1756706
82Glaukos, Section 10b CEO totalDEF 14A2026-04-160001193125-26-157829CEO total compensation as printed in Glaukos's own proxy. As printed: 12,034,087. Filing ↗machine: r6 · c38 · span 1876942–1876952
83Nevro, Section 10b CEO totalDEF 14A2024-04-120000950170-24-044100CEO total compensation as printed in Nevro's own proxy. As printed: 11,453,548. Filing ↗machine: r2 · c16 · span 631983–631993
84Vericel, Section 10b CEO totalDEF 14A2026-03-190001308179-26-000094CEO total compensation as printed in Vericel's own proxy. As printed: 11,156,368. Filing ↗machine: t258 · r1 · c27 · span 627744–627754
85iRhythm Technologies, Section 10b CEO totalDEF 14A2026-04-170001388658-26-000030CEO total compensation as printed in iRhythm Technologies's own proxy. As printed: 11,003,163. Filing ↗machine: r2 · c21 · span 1123498–1123508
86Alphatec Holdings, Section 10b CEO totalDEF 14A2026-04-290001193125-26-191867CEO total compensation as printed in Alphatec Holdings's own proxy. As printed: 10,260,507. Filing ↗machine: t26 · r2 · c25 · span 858148–858158
87AtriCure, Section 10b CEO totalDEF 14A2026-04-060001323885-26-000010CEO total compensation as printed in AtriCure's own proxy. As printed: 9,217,620. Filing ↗machine: span 743364–743373
88AxoGen, Section 10b CEO totalDEF 14A2026-04-290000805928-26-000057CEO total compensation as printed in AxoGen's own proxy. As printed: 9,047,454. Filing ↗machine: r2 · c45 · span 557309–557318
89SI-BONE, Section 10b CEO totalDEF 14A2026-04-210001459839-26-000049CEO total compensation as printed in SI-BONE's own proxy. As printed: 7,453,235. Filing ↗machine: r3 · c18 · span 626969–626978
90Orthofix Medical, Section 10b CEO totalDEF 14A2026-04-290001193125-26-191716CEO total compensation as printed in Orthofix Medical's own proxy. As printed: 7,310,039. Filing ↗machine: t96 · r4 · c16 · span 1472329–1472338
91Tandem Diabetes Care, Section 10b CEO totalDEF 14A2026-04-070001438133-26-000034CEO total compensation as printed in Tandem Diabetes Care's own proxy. As printed: 6,858,503. Filing ↗machine: r3 · c27 · span 866963–866972
92Treace Medical Concepts, Section 10b CEO totalDEF 14A2026-04-060001630627-26-000005CEO total compensation as printed in Treace Medical Concepts's own proxy. As printed: 5,405,190. Filing ↗machine: t81 · r4 · c16 · span 1034150–1034159
93Inari Medical, Section 10b CEO totalDEF 14A2024-03-130001193125-24-066805CEO total compensation as printed in Inari Medical's own proxy. As printed: 5,083,365. Filing ↗machine: r2 · c31 · span 454508–454517
94LeMaitre Vascular, Section 10b CEO totalDEF 14A2026-04-140001193125-26-153877CEO total compensation as printed in LeMaitre Vascular's own proxy. As printed: 3,780,990. Filing ↗machine: r3 · c18 · span 564038–564047
95Paragon 28 (subject), Section 10b CEO totalDEF 14A2024-04-050001193125-24-088613CEO total compensation as printed in Paragon 28's own proxy. As printed: 3,232,420. Filing ↗machine: t193 · r2 · c31 · span 598805–598814
96Cryoport, Section 10b CEO totalDEF 14A2026-04-220001140361-26-016129CEO total compensation as printed in Cryoport's own proxy. As printed: 2,375,524. Filing ↗machine: t277 · r2 · c22 · span 1285130–1285139
97Section 10a, Inari Medical reciprocityDEF 14A—0001193125-24-066805Inari Medical's most recent proxy was read; its disclosed peer group does not include Paragon 28. Filing ↗
98Section 10a, AxoGen reciprocityDEF 14A—0000805928-26-000057AxoGen names Paragon 28 in its own disclosed peer group (read from its most recent proxy). Filing ↗
99Section 10a, iRhythm Technologies reciprocityDEF 14A—0001388658-26-000030iRhythm Technologies's most recent proxy was read; its disclosed peer group does not include Paragon 28. Filing ↗
100Section 10a, Alphatec Holdings reciprocityDEF 14A—0001193125-26-191867Alphatec Holdings's most recent proxy was read; its disclosed peer group does not include Paragon 28. Filing ↗
101Section 10a, AtriCure reciprocityDEF 14A—0001323885-26-000010AtriCure's most recent proxy was read; its disclosed peer group does not include Paragon 28. Filing ↗
102Section 10a, Glaukos reciprocityDEF 14A—0001193125-26-157829Glaukos's most recent proxy was read; its disclosed peer group does not include Paragon 28. Filing ↗
103Section 10a, LeMaitre Vascular reciprocityDEF 14A—0001437749-23-010217LeMaitre Vascular's most recent proxy was read; its disclosed peer group does not include Paragon 28. Filing ↗
104Section 10a, Nevro reciprocityDEF 14A—0000950170-24-044100Nevro's most recent proxy was read; its disclosed peer group does not include Paragon 28. Filing ↗
105Section 10a, Orthofix Medical reciprocityDEF 14A—0001193125-26-191716Orthofix Medical's most recent proxy was read; its disclosed peer group does not include Paragon 28. Filing ↗
106Section 10a, SI-BONE reciprocityDEF 14A—0001459839-26-000049SI-BONE names Paragon 28 in its own disclosed peer group (read from its most recent proxy). Filing ↗
107Section 10a, Silk Road Medical reciprocityDEF 14A—0001397702-24-000024Silk Road Medical's most recent proxy was read; its disclosed peer group does not include Paragon 28. Filing ↗
108Section 10a, Tandem Diabetes Care reciprocityDEF 14A—0001438133-26-000034Tandem Diabetes Care's most recent proxy was read; its disclosed peer group does not include Paragon 28. Filing ↗
109Section 10a, Treace Medical Concepts reciprocityDEF 14A—0001630627-26-000005Treace Medical Concepts's most recent proxy was read; its disclosed peer group does not include Paragon 28. Filing ↗
110Section 10a, Vericel reciprocityDEF 14A—0001308179-26-000094Vericel's most recent proxy was read; its disclosed peer group does not include Paragon 28. Filing ↗

The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.

You'll confirm on The Pay Desk's sign-up page.